Navigation Links
MedSolutions Announces Program to Reduce Unnecessary Implantable Cardiac Defibrillator Surgeries
Date:11/10/2011

FRANKLIN, Tenn., Nov. 10, 2011 /PRNewswire/ -- MedSolutions, a leading provider of quality-driven medical cost management services, today announced the launch of its Implantable Cardioverter Defibrillator (ICD) Surgery Management Program, which uses evidence-based guidelines to ensure the clinical appropriateness of ICD and CRT-D (cardiac resynchronization therapy defibrillator) implantation and directs members to the most qualified physicians and facilities.

With the cost of each ICD/CRT-D procedure averaging $34,000(1) and 157,082 procedures being performed annually,(2) the ICD/CRT-D market represents approximately $5.3 billion in cost per year in the United States. In addition, the estimated annual growth rate of ICD/CRT-D procedures is 11% to 14% respectively.(3)

While clinical guidelines dictate waiting three months after diagnosis of heart failure and at least 40 days after a heart attack before ICD/CRT-D implantation, many physicians take a more aggressive approach to surgery. Earlier implantation has not been shown to benefit patients and, in some cases, the physicians or facilities providing the surgery may lack knowledge of evidence-based guidelines for ICD implants.(4)

Studies have shown that as many as 22.5% of ICD/CRT-D surgeries fail to meet established clinical guidelines, putting patients at greater risk for serious complications, including cardiac perforation, infection, and even death. According to one recent study, patients who received an ICD despite failing to meet evidence-based guidelines had "significantly higher" risks of post-procedure complications and in-hospital death, as well as longer hospital stays, than individuals who met evidence-based criteria.(5)

"ICD surgery is an effective and beneficial treatment for tens of thousands of patients, but it can be extremely harmful when performed outside of accepted guidelines," said Gregg Allen, M.D., chief medical officer of MedSolutions. "Not only do unnecessary ICD surgeries put patients at risk for a number of life-threatening issues, they also represent avoidable health care costs of up to $36,000 per procedure,(6) not including co-pays or additional costs to treat adverse outcomes."

MedSolutions' Implantable Cardioverter Defibrillator Surgery Management program uses evidence-based clinical guidelines built upon the latest guidelines from the American College of Cardiology, American Heart Association, and Heart Rhythm Society and provides a dedicated cardiac queue, including cardiologists and nurses experienced with the complexities of cardiac care, to determine whether ICD implantations are clinically appropriate.

"By reducing unnecessary and inappropriate ICD/CRT-D surgeries and ensuring that patients who require surgery are directed to experienced physicians and quality facilities, our program helps improve health outcomes while limiting unnecessary costs associated with the procedure," Dr. Allen said. "As a result, members experience improved outcomes and payors can reduce total claims costs related to cardiac implantables by 10% to 15%."(7)

About MedSolutions

Using independently validated savings methodologies, MedSolutions specializes in quality-driven intelligent cost management of medical services for commercial, Medicare, and Medicaid payors. The company maintains management contracts for more than 33 million individuals nationwide. Using robust data, predictive intelligence technology and evidence-based clinical expertise, the company's innovative solutions extend beyond Radiology Management to other areas of medical specialty, including Oncology, Cardiac Imaging, Sleep, Ultrasound, Lumbar Spine Surgery, and MedSolutions' groundbreaking Premerus® Diagnostic Accuracy program – the nation's first solution for reducing diagnostic error rates to improve the quality and cost of care. MedSolutions has been recognized for outstanding customer service and effective call center management by the International Customer Management Institute and for four consecutive years by the prestigious J.D. Power and Associates Award. Visit www.medsolutions.com.

Contact: Rebecca Kirkham
Lovell Communications
(615) 297-7766

(1) Boston Scientific. (July 30, 2011). "CMS Issues 2011 Final Inpatient Rule: CMS Reimbursement Update."

(2)  Hammill, et al. (September 2010). "Review of the Registry's Fourth Year, Incorporating Lead Data and Pediatric ICD Procedures, and Use as a National Performance Measure." National ICD Registry Annual Report 2009.

(3)  Sg2. (2011). "Impact of Change" v. 10.0, NIS Analysis

(4)  Al-Khatib, et al. (January 5, 2011).  "Non-Evidence-Based ICD Implantations in the United States." JAMA 305.1:43-49,26 http://jama.ama-assn.org/content/305/1/43.full

(5)  Ibid, 4

(6)  Boston Strategic Partners. (September 2011) "Cardiac Procedure Cost Assessment."  

(7)  MedSolutions Data on File


'/>"/>
SOURCE MedSolutions
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MedSolutions Suggests Use of Technology to Expand Access to Expertise Is Key to Early Breast Cancer Diagnosis and Treatment
2. MedSolutions Applauds Renewed Focus on the Dangers of Radiation Exposure
3. MedSolutions Offers Free CME Credit Imaging Safety Webinar for Physicians
4. MedSolutions Introduces Spine Surgery Management Program
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., a ... design, and immune-engineering today announced the launch of ... development of personalized therapeutic cancer vaccines. EpiVax has ... exclusive access to enabling technologies to the new ... will lead EpiVax Oncology as Chief Executive Officer. ...
(Date:9/19/2017)... 2017   ZirMed Inc ., a recognized leader in ... it has been ranked #1 by its users for the ... 2017 User Survey. ZirMed was recognized as the top-ranked end-to-end ... medical centers over 200 beds and holds one of the ... survey history. ...
(Date:9/12/2017)... Sept. 12, 2017  Consumer reviews on the independent review site ... the number one company for hearing aids, ranking it higher than ... brands. ... #1 by Consumers For Hearing Aids ... Hearing is an online store that provides high performance, state-of-the-art, German-engineered ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... As health professionals work ... as “patient engagement.” The patient is doing more than filling out a survey; in ... “There is an increasing emphasis in health care and research on the importance of ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, along ... updates for the primary prevention of cardiovascular diseases during the 15th Annual ...
(Date:10/13/2017)... York, NY (PRWEB) , ... October 13, 2017 , ... ... influential people in business to advocate for action towards gender equality at their inaugural ... views from around the globe, and reached a social audience of over 3 million. ...
(Date:10/13/2017)... ... , ... “The Journey: From the Mountains to the Mission Field”: the story ... the Philippines. “The Journey: From the Mountains to the Mission Field” is the creation ... has taught all ages and currently teaches a class of ladies at her church, ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... to meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s ... experts and tested to meet the highest standard. , These products are ...
Breaking Medicine News(10 mins):